Last updated: November 1, 2026
Monistat is a mature U.S. over-the-counter vaginal antifungal brand owned by Prestige Consumer Healthcare through its Insight Pharmaceuticals portfolio. Its commercial value comes from brand recognition, retail distribution, and product-format breadth rather than active-ingredient exclusivity. The primary ingredient, miconazole nitrate, is an established generic compound marketed under the FDA’s nonprescription vaginal antifungal framework.
Prestige does not disclose Monistat revenue separately. Its reported financial trajectory therefore provides a portfolio-level proxy, not a brand-specific valuation. Monistat faces persistent pressure from retailer private labels, generic miconazole products, prescription fluconazole, and lower-cost alternative treatments. The brand remains defensible through consumer awareness, shelf placement, formulation variety, and marketing, but its legal barriers to entry are limited.
Who owns Monistat and how is the brand positioned?
Prestige Consumer Healthcare is the current owner of Monistat in the United States. Monistat is part of Prestige’s OTC Healthcare portfolio, which includes brands such as Dramamine, Clear Eyes, BC, GoodSense, Chloraseptic, and Summer’s Eve. Prestige acquired Insight Pharmaceuticals in 2014, adding Monistat and other consumer-health brands to its portfolio.[1]
Monistat is positioned as a branded treatment for vaginal yeast infections. Its principal U.S. products use miconazole nitrate in different doses and treatment durations:
| Product |
Active ingredient |
Typical treatment duration |
Dosage form |
| Monistat 1 |
Miconazole nitrate, 1,200 mg |
One day |
Vaginal ovule |
| Monistat 3 |
Miconazole nitrate, 200 mg per dose |
Three days |
Vaginal suppositories or cream |
| Monistat 7 |
Miconazole nitrate, 100 mg per dose |
Seven days |
Vaginal suppositories or cream |
| Monistat external cream |
Miconazole nitrate, generally 2% |
Symptom relief |
Topical cream |
Product availability, packaging, and exact labeling can vary by retailer and market. DailyMed identifies miconazole nitrate as the active ingredient in Monistat vaginal products.[2]
The brand’s commercial proposition is convenience. Monistat offers one-day, three-day, and seven-day treatment options, allowing consumers to trade off treatment duration, price, and perceived convenience.
How large is the Monistat market?
The relevant market is the U.S. vaginal antifungal market, which includes branded OTC products, generic miconazole products, clotrimazole products, tioconazole products, and prescription therapies such as oral fluconazole.
Public sources do not provide a separately audited Monistat market-share or revenue figure. The market is economically attractive because:
- Vaginal yeast infections are common and frequently treated in the retail channel.
- The condition is suited to self-care when symptoms are familiar and uncomplicated.
- Treatment is generally purchased through pharmacies, mass merchants, grocery stores, and e-commerce.
- Consumers can switch among branded, generic, and private-label products without changing the underlying active ingredient.
- The category has recurring demand but limited treatment duration, which constrains repeat purchase frequency.
Monistat competes on brand trust and recognition, while private-label products compete primarily on price. Retailers can place generic miconazole products next to Monistat because both products can comply with the same FDA OTC requirements when they use permitted active ingredients, concentrations, dosage forms, and labeling.
The category also competes with prescription treatment. Fluconazole is often preferred by consumers who seek a single oral dose through a clinician or telehealth provider. This creates a substitution risk for OTC vaginal products, although OTC therapy remains more accessible and does not require a prescription.
What is the financial trajectory of Monistat’s owner?
Prestige reports consolidated and segment results, but not revenue or profit for Monistat. The company’s financial trajectory is therefore the best public indicator of the brand’s operating environment.
| Prestige fiscal year |
Approximate consolidated net revenue |
Relevance to Monistat |
| FY2020 |
$927 million |
Mature OTC portfolio base |
| FY2021 |
$951 million |
Portfolio growth and consumer-health demand |
| FY2022 |
$965 million |
Continued expansion with mixed category conditions |
| FY2023 |
$1.01 billion |
Scale increased through brand portfolio performance |
| FY2024 |
$1.03 billion |
Stable large-scale OTC platform |
Prestige’s filings report consolidated results and broader operating segments rather than individual brand sales. Monistat’s contribution cannot be isolated from the public financial statements.[1]
The financial profile of Monistat is likely different from that of a prescription product. Its economics depend on:
- Retail price and trade spending. Brand pricing must support a premium over generic miconazole while remaining acceptable to consumers.
- Advertising efficiency. Marketing supports brand recall in a category where the active ingredient is widely available.
- Retail distribution. Out-of-stock events or reduced shelf placement can shift purchases to private-label competitors.
- Product mix. One-day products can produce higher price points, while seven-day products may appeal to value-oriented consumers.
- Input and logistics costs. Packaging, applicators, tubes, ovules, and retail distribution affect gross margin.
- Seasonality. Demand can vary with consumer behavior, healthcare utilization, and retail promotional calendars.
Monistat is likely a cash-generative mature brand, but its growth ceiling is limited by generic substitution and the age of the active ingredient. Its financial trajectory is more likely to depend on pricing, distribution, brand support, and portfolio management than on volume expansion.
What patents protect Monistat?
No currently material composition-of-matter patent protects miconazole nitrate. The active ingredient has been available for decades, and generic manufacturers can market miconazole products subject to applicable FDA requirements.
Monistat’s principal protection is commercial and regulatory rather than pharmaceutical patent exclusivity:
| Protection category |
Monistat position |
| Composition-of-matter patent |
No meaningful current exclusivity |
| Orange Book listing |
Generally not applicable to OTC monograph products |
| Hatch-Waxman exclusivity |
Not the primary regulatory framework |
| OTC monograph compliance |
Core regulatory pathway |
| Trademark |
MONISTAT brand and associated trade dress |
| Packaging and labeling |
Protectable, but easy to design around |
| Formulation know-how |
Potentially useful, but limited barrier for standard products |
| Retail distribution |
Important commercial barrier |
| Consumer recognition |
Major practical defense against substitution |
The FDA regulates OTC vaginal antifungal products under the nonprescription monograph system. The FDA’s M005 OTC monograph covers vaginal antifungal drug products, including permitted active ingredients and conditions of use.[3]
Monistat may have product-specific trademarks, packaging rights, and internal manufacturing or supply arrangements. Those rights do not prevent a competitor from selling an equivalent miconazole product under a different brand.
What formulations are protected by Monistat?
Monistat’s formulation portfolio is commercially differentiated but not strongly protected by patent exclusivity. The main variations are:
- Single-dose ovule products.
- Three-day vaginal suppository products.
- Seven-day vaginal suppository products.
- Internal vaginal creams.
- External creams for symptom relief.
- Combination packages containing internal treatment and external cream.
The one-day, three-day, and seven-day formats create segmentation within the brand. They also allow Prestige to maintain multiple price points and shelf positions.
A competitor can generally design around Monistat’s packaging and trade dress while selling the same active ingredient in a comparable dosage form. The practical barriers include manufacturing consistency, packaging compliance, applicator design, retail acceptance, and consumer acquisition costs.
When does Monistat lose exclusivity?
Monistat does not have a conventional prescription patent-expiration date that determines generic entry. Its active ingredient is already off-patent, and OTC competitors can enter through applicable monograph or other FDA pathways.
The relevant exclusivity dates are therefore:
| Exclusivity type |
Status |
| Active-ingredient patent exclusivity |
Expired |
| Prescription-drug exclusivity |
Not applicable to the core OTC brand |
| OTC monograph protection |
Applies to compliant products, not to Monistat alone |
| Trademark protection |
Continues while registrations are maintained and used |
| Brand-specific market exclusivity |
None in the Hatch-Waxman sense |
A generic manufacturer does not need to wait for a Monistat patent to expire. It can market a compliant miconazole product independently of the Monistat brand.
What is the Orange Book status of Monistat?
Monistat is generally outside the standard Orange Book patent-listing and Paragraph IV framework because its principal products are OTC drugs marketed under the FDA’s monograph system.
The Orange Book primarily identifies approved prescription drug products and related patent and exclusivity information. An OTC monograph product does not ordinarily create the same patent-certification process as an NDA product. As a result:
- Monistat does not have a conventional Orange Book patent estate driving market exclusivity.
- Generic OTC manufacturers generally do not need to file Paragraph IV certifications against Monistat.
- A Monistat-related patent dispute would more likely involve formulation, packaging, trademark, advertising, or manufacturing issues than a standard Hatch-Waxman patent case.
Are there Paragraph IV challenges or generic litigation involving Monistat?
There is no standard Paragraph IV challenge pathway for the core Monistat OTC monograph products. The absence of an Orange Book-listed patent estate reduces the likelihood of a conventional ANDA litigation campaign.
The relevant competitive activity is ordinary OTC substitution. Generic and private-label manufacturers can compete through:
- Miconazole vaginal creams.
- Miconazole suppositories.
- Miconazole ovules.
- Clotrimazole products.
- Tioconazole products.
- Store-brand combination packs.
- Online direct-to-consumer products.
No material public Monistat-specific patent litigation or settlement agreement is identified in Prestige’s public financial disclosures cited here.[1]
This does not eliminate legal risk. Prestige could still face or bring disputes involving:
- MONISTAT trademark rights.
- False or misleading comparative advertising.
- Package similarity and trade dress.
- Product quality or manufacturing claims.
- Distribution agreements.
- Private-label supply relationships.
- Consumer class actions concerning labeling or product performance.
These risks are different from patent litigation and generally do not create durable market exclusivity.
Which companies challenge Monistat?
Monistat’s competitive set includes branded OTC companies, store-brand manufacturers, generic drug companies, and prescription providers.
| Competitor type |
Examples |
Competitive advantage |
| Branded OTC products |
Vagisil antifungal products, other national brands |
Consumer awareness and retail presence |
| Retail private labels |
CVS, Walgreens, Walmart, Target, Amazon and other store brands |
Lower price and retailer placement |
| Generic manufacturers |
Suppliers of miconazole, clotrimazole, and tioconazole |
Low-cost manufacturing and price |
| Prescription providers |
Fluconazole manufacturers, telehealth platforms |
Oral treatment and clinician interaction |
| International brands |
Local antifungal brands outside the U.S. |
Country-specific distribution and recognition |
The most direct threat is private-label miconazole because it can replicate the product’s therapeutic proposition at a lower price. National branded competitors matter most when they secure preferred shelf placement or gain consumer attention through advertising.
How strong is the Monistat patent estate?
The patent estate is weak as a barrier to generic entry but the commercial estate is stronger.
| Asset |
Strength |
Business impact |
| Active ingredient |
Low |
Miconazole is generic and widely available |
| Formulation patents |
Low to moderate |
Standard dosage forms are difficult to fence off |
| Trademark |
Moderate to strong |
Supports brand recognition and limits confusingly similar branding |
| Consumer trust |
Moderate to strong |
Can preserve a price premium |
| Retail distribution |
Moderate |
Shelf access and planograms support volume |
| Marketing assets |
Moderate |
Helps maintain awareness but requires ongoing spending |
| Manufacturing know-how |
Low to moderate |
Can support quality and supply reliability |
| Regulatory position |
Moderate |
Monograph compliance enables continued OTC sales but does not block entry |
Monistat’s defensibility is strongest where consumers value a known brand and where retailers support the brand with prominent placement. It is weakest in price-sensitive purchases and online channels, where consumers can compare equivalent active ingredients quickly.
What generic entry risks exist for Monistat?
The generic entry risk is continuous rather than event-driven. There is no single patent cliff. Price competition can intensify whenever:
- Retailers expand private-label shelf space.
- Online sellers improve product visibility.
- Generic manufacturers reduce wholesale pricing.
- Consumers become more comfortable comparing active ingredients.
- Retailers consolidate purchasing power.
- Prescription and telehealth access becomes easier.
- Consumers trade down during periods of household budget pressure.
A generic launch would not need to wait for a Monistat patent expiration. The likely effect would be gradual share erosion and lower realized pricing rather than an abrupt loss of all sales.
The highest-risk products are standard miconazole formats that are easy to replicate. The lower-risk products are combinations with strong brand packaging, differentiated consumer instructions, or retailer-specific merchandising.
What is the FDA regulatory status of Monistat?
Monistat is marketed as an OTC vaginal antifungal product. The relevant FDA framework is the OTC monograph for vaginal antifungal drug products, identified by the FDA as M005.[3]
Regulatory obligations include:
- Use of permitted active ingredients and concentrations.
- Required product labeling.
- Appropriate warnings and directions.
- Manufacturing under applicable current good manufacturing practice requirements.
- Compliance with FDA registration, listing, and postmarket obligations.
- Advertising and promotional compliance.
The OTC monograph pathway reduces regulatory cost relative to a new prescription NDA. It also reduces the ability of the brand owner to use regulatory exclusivity as a competitive moat.
Does Monistat face biosimilar risk?
No. Monistat is a small-molecule OTC antifungal product, not a biologic. Biosimilar competition does not apply.
The relevant substitution risks are generic small-molecule products, private-label OTC products, alternative antifungal ingredients, and prescription fluconazole.
What licensing deals affect Monistat?
The principal publicly visible ownership event is Prestige Consumer Healthcare’s acquisition of Insight Pharmaceuticals, which brought Monistat into the Prestige portfolio.[1]
No Monistat-specific licensing arrangement is central to the brand’s public financial profile. The commercial model is primarily based on ownership, manufacturing or contract supply, retailer distribution, and brand marketing rather than a royalty-bearing innovation license.
What geographic markets does Monistat cover?
Monistat is principally a U.S. OTC brand. Its value is concentrated in the U.S. retail healthcare market, where the brand has broad pharmacy, mass-market, grocery, and e-commerce distribution.
International opportunity is more limited because:
- Vaginal antifungal brands differ by country.
- Regulatory classifications vary between prescription and OTC status.
- Miconazole and alternative antifungals may have stronger local brands.
- Retail distribution and consumer treatment habits vary by market.
- The Monistat name may not have equivalent recognition outside the United States.
The U.S. market remains the primary basis for assessing Monistat’s revenue exposure and competitive risk.
What generic launch scenarios could affect Monistat revenue?
| Scenario |
Likely market effect |
Financial effect |
| Stable branded demand |
Monistat retains shelf space and price premium |
Low-single-digit growth or stable revenue |
| Moderate private-label expansion |
Consumers trade down in routine purchases |
Volume and pricing pressure |
| Aggressive online generic competition |
More transparent price comparison |
Faster share loss and lower net pricing |
| Increased fluconazole and telehealth use |
Some consumers shift to oral prescription treatment |
Reduced OTC category volume |
| Successful brand innovation |
New packaging, combinations, or consumer education |
Supports premium and retailer support |
The most probable outcome is gradual erosion rather than a sudden launch-driven collapse. Monistat can preserve value if Prestige maintains brand investment, secures retailer distribution, and manages price gaps against store brands.
What is the revenue exposure of Prestige to Monistat?
Monistat’s precise revenue exposure is not publicly disclosed. Prestige reports portfolio-level financial results, and Monistat is grouped with other consumer-health brands.
That reporting structure limits external valuation precision. Investors can assess:
- Prestige’s consolidated revenue.
- OTC Healthcare segment performance.
- Gross margin and adjusted EBITDA.
- Advertising and promotional spending.
- Acquisition activity.
- Portfolio concentration.
They cannot calculate Monistat revenue or EBITDA from the company’s public filings without nonpublic operating data.
For valuation purposes, Monistat should be treated as a mature branded OTC asset with relatively low patent risk, moderate brand-equity value, and high sensitivity to price competition.
Key Takeaways
- Monistat is owned by Prestige Consumer Healthcare through its Insight Pharmaceuticals portfolio.
- Its core products use off-patent miconazole nitrate.
- The brand does not depend on a conventional patent-expiration date.
- OTC monograph compliance, not Orange Book exclusivity, is the main FDA framework.
- Paragraph IV litigation is not the normal competitive mechanism.
- Private-label and generic miconazole products are the principal threats.
- Fluconazole and telehealth create additional substitution pressure.
- Monistat revenue is not separately disclosed.
- Prestige’s consolidated revenue has grown from roughly $927 million in FY2020 to about $1.03 billion in FY2024, but this does not establish Monistat-specific growth.
- The brand’s strongest assets are recognition, distribution, treatment-format breadth, and consumer trust.
- The brand’s weakest protection is its lack of composition-of-matter or product-specific market exclusivity.
FAQs About Monistat Market and Patent Risk
Is Monistat a patented drug?
The active ingredient in Monistat, miconazole nitrate, is an established off-patent compound. Monistat’s protection comes primarily from trademarks, packaging, distribution, and brand recognition.
Can stores sell generic Monistat?
Stores can sell generic or private-label miconazole products when those products comply with FDA requirements for OTC vaginal antifungal products. They cannot use Monistat trademarks or confusingly similar branding.
Is Monistat listed in the FDA Orange Book?
The core OTC Monistat products are generally not governed by the Orange Book patent-listing process because they are marketed under the OTC monograph framework.
Who manufactures Monistat?
Prestige Consumer Healthcare owns the brand. Manufacturing may involve company facilities or qualified contract manufacturers, but brand-level manufacturing arrangements are not fully disclosed in public filings.
What would cause Monistat sales to decline fastest?
The fastest risks are a large increase in private-label shelf space, substantial generic price discounts, weaker retailer distribution, or increased consumer use of prescription fluconazole through telehealth and primary-care channels.
References
- Prestige Consumer Healthcare, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended March 31, 2024. U.S. Securities and Exchange Commission. https://www.sec.gov/ixviewer/documents/
- National Library of Medicine. (n.d.). DailyMed: Monistat vaginal antifungal products. https://dailymed.nlm.nih.gov/dailymed/
- U.S. Food and Drug Administration. (2022). OTC Monograph M005: Vaginal antifungal drug products for over-the-counter human use. https://www.accessdata.fda.gov/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
